Reagent | LDL Cholesterol
Exceptional correlation with standard methods
A correlation coefficient of r=0.99 was found when measured against the Ultracentrifugation method
Wide measuring range
With a measuring range of 0.189 – 26.1 mmol/l, it will comfortably detect levels outside of the healthy limit of 4.90 mmol/l
Stable to expiry when stored at 2-8°C
- Direct Clearance Method
- Liquid ready-to-use reagents
- Correlation coefficient of r=0.99 with Ultracentrifugation method
- Stable to expiry when stored at 2-8°C
- Measuring range 0.189 – 26.1 mmol/l
Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers. Contact us to enquire about your specific analyser.
What is LDL Cholesterol assay used for?
Low Density Lipoproteins (LDL) are synthesised in the liver by the action of various Lipolytic enzymes on triglyceride rich Very Low Density Lipoproteins (VLDLs). Specific LDL receptors exist to facilitate the elimination of LDL from plasma by liver parenchymal cells. It has been shown that most of the cholesterol stored in atherosclerotic plaques originates from LDL. For this reason the LDL-Cholesterol concentration is considered to be the most important clinical predictor, of all single parameters, with respect to coronary atherosclerosis.
Accurate measurement of LDL-Cholesterol is of vital importance in therapies which focus on lipid reduction to prevent atherosclerosis or reduce its progress and to avoid plaque rupture.
It is recommended a patient get tested when aged 40; as part of a routine CV health check; if they are already thought to be at risk of CVD for another reason; or to monitor their response to treatments which lower LDL Cholesterol.
- Moloney, F., et al. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus 1,2,3. Am. J. Clin. Nutr. 2004, 80(4): 887-895
- Nowak, M., et al. Changes in lipid metabolism in women with age-related macular degeneration. Clin. Exp. Med., 2005, 4(4): 183-187
- Chen, C-W and Cheng, H-H. A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes. J. Nutr. 2006, 136: 1472-1476
- Moreira Lima, L., et al. Níveis Plasmàticos Elevados de Lipoproteína(a) Correlacionados com a Gravidade da Doenca Arterial Coronariana em Pacientes Submetidos à Angiografia (Increased Serum Levels of Lipoprotein(a) Correlated with the Severity of Coronary Artery Disease in Patients Submitted to Angiography. Arquivos Brasileiros de Cardiologia. 2006, 87(3): 260-266
- Chou T-W., et al. A Rice bran oil diet improves lipid abnormalities and suppress hyperinsulinemic responses in rats with streptozotocin/nicotinamide-induced Type 2 diabetes. J.Clin. Biochem.Nutr. 2009, 45(1): 29-36
- Rhodes, P., et al. Adult-onset obesity reveals prenatal programming of glucose-insulin sensitivity in male sheep nutrient restricted during late gestation. PloS ONE 2009, 4(10): e7393
- Wonnacott, K.E. et al. Dietary omega-3 and-6 polyunsaturated fatty acids affect the composition and development of sheep granulose cells, oocytes and embryos. Reproduction. 2010, 139(1): 57-69
- Ganguli, D., et al. Association between inflammatory markers and cardiovascular risk factors in women from Kolkata, W.B, India. Arq. Bras. Cardiol. 2011, 96(1): Epub
- Srinivasa, G., et al. Comparison between serum insulin levels and its resistance with biochemical, clinical and anthropometric parameters in South Indian children and adolescents. Ind. J. Biochem. 2011, 26(1): 22-27
- Yahaya, N. et al. Type 2 diabetes with good glycemic control have improved insulin response and lower non-esterified fatty acid level after a meal challenge. Journal of Diabetes Mellitus 2012, 2(1): 1-7
The aim of Biomedical Science Day is to raise the public’s awareness of the importance of biomedical science and the vital role it plays in the world. Randox are dedicated to improving healthcare worldwide through placing a major focus on research and development. The Randox scientists work in pioneering research into a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease.
A recent blog from Doris-Ann Williams, the Chief Executive at BIVDA, explains how “increased funding is not enough to sustain the NHS” and how “we need to make better use of in vitro diagnostics to ensure a successful future”.
The National Health Service (NHS) is a publicly funded, primarily taxation, national healthcare system in the United Kingdom. It was first set-up on July 5th, 1948 by Aneurin Bevan as he believed that everyone, regardless of wealth, should have access to good healthcare. Whilst the NHS is an extremely important aspect of healthcare in the UK, in vitro diagnostics are the heart and soul of the healthcare system as healthcare professionals not only rely on blood tests to diagnose and treat patients, but also to rule out the different contributing causes to a disease state. In vitro diagnostics also plays a key role in monitoring chronic disease states. In vitro diagnostics can also aid in reducing hospital stays, reduce misdiagnosis and support patients in looking after their own health and to deliver personalised treatment plans.
The Randox scientists have developed several niche assays to improve patient diagnosis, monitor treatment and eliminate misdiagnosis.
Adiponectin is a protein hormone secreted by adipocytes with anti-inflammatory and insulin-sensitising properties. It plays an important role in a number of metabolic processes including glucose regulation and fatty acid oxidation. Adiponectin levels are inversely correlated with abdominal visceral fat which have proven to be a strong predictor of several pathologies, including: metabolic syndrome, type 2 diabetes mellitus (T2DM), cancers and cardiovascular disease (CVD). For more information on the importance of testing Adiponectin levels, check out our Adiponectin Whitepaper.
Cystatin C is an early risk marker for renal impairment. The most commonly run test for renal impairment is Creatinine. Creatinine measurements have proven to be inadequate as certain factors must be taken into consideration, including age, gender, ethnicity etc. The National Institute for Health and Care Excellence (NICE) have updated their guidelines, which now recommends Cystatin C as a more superior test for renal impairment due to its higher specificity for significant disease outcomes than those based on Creatinine. For more information on the importance of testing Cystatin C levels, check out our Cystatin C Whitepaper.
Small-dense LDL Cholesterol (sdLDL-C)
LDL Cholesterol (LDL-C) consists of two parts: the large and buoyant LDL Cholesterol and the small and dense LDL Cholesterol. Whilst all LDL-C transports triglycerides and cholesterol to bodily tissues, their atherogensis varies according to their size. As sdLDL-C is small and dense, they can more readily permeate the arterial wall and are more susceptible to oxidation. Research indicates that individuals with a predominance of sdLDL-C have a 3-fold increased risk of myocardial infarction. It has been noted that sdLDL-C carries less Cholesterol than large LDL, therefore a patient with predominately sdLDL-C particle may require nearly 70% more sdLDL-C particles to carry the same amount of cholesterol as the patient with predominately LDL-C particles. For more information on the importance of testing sdLDL-C levels, check out our sdLDL-C Whitepaper.
These three niche in vitro diagnostics tests developed by Randox scientists can aid in reducing NHS costs due to their higher performance compared to the traditional tests. Randox are constantly striving to improve healthcare worldwide.
For more information on the extensive range of Randox third-party in vitro diagnostic reagents, visit: https://www.randox.com/diagnostic-reagents/ or contact firstname.lastname@example.org.